Kliniken Maria Hilf GmbH Moenchengladbach
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department is conducting studies on heart failure in patients with concurrent kidney dysfunction, evaluating novel drug combinations to reduce cardiovascular mortality. Research also targets anterior ST‑elevation myocardial infarction outcomes and strategies to improve blood pressure control in high‑risk individuals.
- Heart failure with reduced renal function
- Outcomes after primary PCI for anterior STEMI
- Hypertension management in patients with cardiovascular disease
- Combination therapy to lower cardiovascular death risk
Kliniken Maria Hilf GmbH Moenchengladbach collaborates with European cardiac networks to bring innovative treatments to patients.
Hemic and Lymphatic Diseases
Clinical trials focus on aggressive blood cancers such as acute lymphoblastic leukemia and mantle cell lymphoma, testing targeted agents and transplant strategies. The site also evaluates therapies for Waldenström’s macroglobulinemia and multiple myeloma, aiming to improve remission depth and quality of life.
- Targeted therapy for mantle cell lymphoma
- Novel regimens for acute lymphoblastic leukemia
- Combination approaches in Waldenström’s macroglobulinemia
- Maintenance strategies after autologous stem‑cell transplantation in myeloma
The research team leverages its expertise in hematology to advance personalized treatment options for patients across the region.
Immune System Diseases
Studies explore immune‑modulating therapies, including eosinophilic asthma treatment with biologics and the use of immune checkpoint inhibitors in various malignancies. The aim is to assess safety, efficacy, and the potential to reduce disease‑related inflammation.
- Biologic add‑on therapy for eosinophilic asthma
- Anti‑PD‑1 antibodies in early‑stage Hodgkin lymphoma
- Combination immunotherapy for high‑risk lymphomas
- Evaluation of novel agents targeting immune pathways
By integrating immunology with oncology, the department seeks to broaden therapeutic horizons for immune‑driven conditions.
Neoplasms
The site conducts extensive cancer research, testing targeted drugs for tumors with specific genetic alterations such as KRAS G12C mutation and high PD‑L1 expression. Trials also address organ preservation in rectal cancer, advanced colorectal cancer therapies, and novel combinations for non‑small cell lung cancer.
- KRAS‑targeted agents in colorectal cancer
- PD‑L1‑guided immunotherapy in non‑small cell lung cancer
- Organ‑preserving approaches for locally advanced rectal cancer
- Combination regimens for advanced anal carcinoma
These investigations aim to improve survival and quality of life for patients with solid tumors across the therapeutic spectrum.
Respiratory Tract Diseases
Research includes trials for non‑small cell lung cancer and extensive‑stage small cell lung cancer, evaluating novel targeted agents and immunotherapy‑radiotherapy combos. Additionally, the department studies severe asthma phenotypes to determine the benefit of new biologic treatments.
- Targeted therapy for ROS1‑positive NSCLC
- Durvalumab combined with optimized radiotherapy for stage III NSCLC
- Immunotherapy in extensive‑stage small cell lung cancer
- Biologic add‑on for eosinophilic asthma uncontrolled by standard inhalers
The clinic’s multidisciplinary approach strives to bring cutting‑edge respiratory care to patients with complex lung diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 79 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1University Of Cologne2active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1University Of Cologne5trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliniken Maria Hilf GmbH Moenchengladbach
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 6 | Unknown | 2014-12-18 | 2025-03-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.